Shares of Sun Pharma Industries Ltd rose 0.75% to touch a day’s high of Rs 1,648.90 on 23rd January. This happened after the company announced that it had received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of the Semaglutide injection for chronic weight management in adults.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight management along with a reduced-calorie diet and increased physical activity. Sun Pharma said the product will be launched under the brand name Noveltreat. This will happen after the Semaglutide patent expires in India.

The approval followed a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths, with a recommended maintenance dose of 2.4 mg administered once weekly. The injection will be offered in a prefilled pen for ease of use and accurate dosing.

Sun Pharma Managing Director Kirti Ganorkar said GLP-1-based therapies can play a key role in addressing India’s growing burden of obesity and diabetes. He added that Noveltreat meets global quality standards and is supported by Indian clinical data.

Separately, in December 2025, Sun Pharma received DCGI approval to market Semaglutide injection for adults with type 2 diabetes. This product will be launched under the brand name Sematrinity after patent expiry.

GLP-1 receptor agonists are widely used to treat diabetes and obesity. Additionally, nearly one in four Indians aged 15–49 are overweight or obese, according to the National Family Health Survey-5.

At 1:16 PM, shares of Sun Pharma were trading 0.58% higher at Rs 1,643.70 on NSE.

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!